BML Capital Management LLC Grows Stock Holdings in Milestone Pharmaceuticals Inc. (NASDAQ:MIST)

BML Capital Management LLC grew its holdings in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 62.3% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 442,352 shares of the company’s stock after purchasing an additional 169,852 shares during the period. Milestone Pharmaceuticals comprises 0.6% of BML Capital Management LLC’s investment portfolio, making the stock its 23rd largest holding. BML Capital Management LLC’s holdings in Milestone Pharmaceuticals were worth $739,000 as of its most recent SEC filing.

Milestone Pharmaceuticals Price Performance

Shares of MIST stock opened at $1.70 on Wednesday. The company has a market capitalization of $90.36 million, a PE ratio of -1.22 and a beta of 1.77. The firm has a fifty day simple moving average of $1.67 and a 200-day simple moving average of $2.09. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 2.97. Milestone Pharmaceuticals Inc. has a twelve month low of $1.33 and a twelve month high of $4.49.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). Equities research analysts anticipate that Milestone Pharmaceuticals Inc. will post -1.15 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on MIST. Piper Sandler decreased their target price on shares of Milestone Pharmaceuticals from $6.00 to $5.00 and set an “overweight” rating for the company in a research note on Tuesday, March 5th. HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of Milestone Pharmaceuticals in a research note on Friday, March 22nd. Finally, TD Cowen decreased their target price on shares of Milestone Pharmaceuticals from $17.00 to $9.00 and set an “outperform” rating for the company in a research note on Wednesday, December 27th.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.